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BACKGROUND. Tumor content in circulating cell-free DNA (cfDNA) is a promising
biomarker, but longitudinal dynamics of tumor-derived and non–tumor-derived cfDNA
through multiple courses of therapy have not been well described.
METHODS. CfDNA from 663 plasma samples from 140 patients with castration-resistant
prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction
(TFx) estimated using the computational tool ichorCNA was correlated with clinical features
and responses to therapy.
RESULTS. TFx associated with the number of bone metastases (median TFx = 0.014 with
no bone metastases, 0.047 with 1–3 bone metastases, 0.190 for 4+ bone metastases; P <
0.0001) and with visceral metastases (P < 0.0001). In multivariable analysis, TFx remained
associated with metastasis location (P = 0.042); TFx was positively correlated with alkaline
phosphatase (P = 0.0227) and negatively correlated with hemoglobin (Hgb) (P < 0.001), but
it was not correlated with prostate specific antigen (PSA) (P = 0.75). Tumor-derived and
non–tumor-derived cfDNA track together and do not increase with generalized tissue
damage from chemotherapy or radiation at the time scales examined. All new treatments
that led to ≥30% PSA decline at 6 weeks were associated with TFx decline when baseline
TFx was >7%; however, TFx in patients being subsequently maintained on secondary
hormonal therapy was quite dynamic.
CONCLUSION. TFx correlates with clinical features associated with overall survival in […]
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Introduction
As treatment options for metastatic prostate cancer expand, choosing the optimal agent, timing, sequenc-
ing, and combinations to maximize clinical benefit has become increasingly challenging. Treating patients 
with ineffective therapy exposes them to unnecessary toxicity while allowing symptomatic progression of  
their cancer. Conversely, early discontinuation of  an agent that is providing some degree of  clinical benefit 
relative to other available modalities or no treatment can also be detrimental. The Prostate Cancer Clinical 
Trials Working Group 3 (PCWG3) guidelines (1) address challenges in efficacy assessment posed by stan-
dard bone scintigraphy, CT, and prostate specific antigen (PSA) assessments and place increased emphasis 
on outcomes that reflect patient benefit, even after initial progression on therapy or after discontinuation of  
BACKGROUND. Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but 
longitudinal dynamics of tumor-derived and non–tumor-derived cfDNA through multiple courses of 
therapy have not been well described.
METHODS. CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate 
cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated 
using the computational tool ichorCNA was correlated with clinical features and responses to 
therapy.
RESULTS. TFx associated with the number of bone metastases (median TFx = 0.014 with no bone 
metastases, 0.047 with 1–3 bone metastases, 0.190 for 4+ bone metastases; P < 0.0001) and 
with visceral metastases (P < 0.0001). In multivariable analysis, TFx remained associated with 
metastasis location (P = 0.042); TFx was positively correlated with alkaline phosphatase (P = 
0.0227) and negatively correlated with hemoglobin (Hgb) (P < 0.001), but it was not correlated with 
prostate specific antigen (PSA) (P = 0.75). Tumor-derived and non–tumor-derived cfDNA track 
together and do not increase with generalized tissue damage from chemotherapy or radiation at the 
time scales examined. All new treatments that led to ≥30% PSA decline at 6 weeks were associated 
with TFx decline when baseline TFx was >7%; however, TFx in patients being subsequently 
maintained on secondary hormonal therapy was quite dynamic.
CONCLUSION. TFx correlates with clinical features associated with overall survival in CRPC, and TFx 
decline is a promising biomarker for initial therapeutic response.
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therapy. Among the recommendations from the PCWG3 is direct biologic characterization of  the tumor at 
the time a new treatment is being considered, including blood-based diagnostics such as circulating nucleic 
acids, to improve understanding of  disease biology and identify potential predictive molecular biomarkers.
Circulating cell-free DNA (cfDNA) derived from patient plasma is attractive as a noninvasive method 
for genetic characterization of  tumor burden, given its high concordance with matched metastatic biopsies 
(2, 3). In addition, both the total quantity of  cfDNA in the circulation and estimates of  the tumor-derived 
contribution to cfDNA (tumor fraction; TFx) have been proposed as prognostic biomarkers (4) and indica-
tors of  response and resistance to therapy (5). One study suggested an association between the total cfDNA 
concentration in the circulation with clinical outcomes after taxane-based chemotherapy in metastatic cas-
tration-resistant prostate cancer (mCRPC) (6), but other studies did not demonstrate an independent cor-
relation on multivariable analysis between baseline cfDNA concentration and outcomes for abiraterone/
enzalutamide (7, 8), taxane chemotherapy (9), or olaparib (5). This may be because total cfDNA concentra-
tion measured in the blood is not a reliable biomarker for tumor burden and is subject to significant techni-
cal and biological variability, sources of  which include reagents and conditions related to DNA isolation, as 
well as biological features that are poorly understood (e.g., levels of  DNase and anti-dsDNA antibodies in 
the circulation, or upregulation or downregulation of  mechanisms of  cfDNA clearance) (10).
As such, we hypothesized that the fraction of  cfDNA derived from tumor cells (i.e., TFx) would be a 
more reliable biomarker of  disease dynamics. TFx is promising as a biomarker of  disease burden and ther-
apeutic response, since — unlike circulating protein tumor markers — this metric is agnostic to cancer type. 
Among the clinical applications of  such a biomarker would be the disambiguation of  radiographic flare or 
pseudoprogression responses after starting new agents (particularly hormonal or immune therapies), or the 
early measurement of  treatment response to allow earlier intensification or discontinuation of  ineffective 
therapy prior to radiographic progression.
We have previously described a method using a software tool called ichorCNA (2) to derive TFx 
through copy number alterations detected by sparse (~0.1× coverage) whole genome sequencing (WGS) (3, 
11), which we termed ultra-low pass WGS (ULP-WGS). Measuring tumor content through quantification 
of  the presence of  individual alleles (12) has demonstrated utility in assessment of  response or resistance to 
therapy in cancers where those alleles are known clonal drivers. An advantage of  ichorCNA is that it does 
not require prior knowledge of  alterations present in that patient’s cancer, while accounting for differences 
in clonality and copy number at each locus. Accounting for both are important features of  ichorCNA as 
compared with quantifying individual alleles; for example, point mutations in genes such as AR (13), EGFR 
(14), and ERBB2 (15) often are associated with amplifications at those loci and may occur within distinct 
subclones, so estimating TFx based on read count of  the alternate allele could be inaccurate in these cases. 
We previously showed that TFx estimated by ULP-WGS using ichorCNA demonstrates close concordance 
with that estimated from whole exome sequencing using a different method for deriving TFx from somatic 
DNA alterations called ABSOLUTE (16, 17), thus validating our method for quantification. We also pre-
viously demonstrated that TFx is correlated with overall survival in metastatic triple-negative breast cancer 
(TNBC) (17). Here, we examine clinical correlations of  TFx in patients with CRPC and assess TFx as a 
biomarker of  tumor burden and disease dynamics in these patients.
Results
Participating patients were identified for inclusion in this study in clinical cohorts as described in the Meth-
ods section. A total of  722 plasma specimens from 164 patients with CRPC were obtained and planned 
for ULP-WGS — 53 banked samples from 50 patients and 669 prospectively collected samples from 114 
patients (Figure 1). Of  the banked samples, 17 were low yield and 3 failed library construction (primarily 
due to inadequate cfDNA extraction from samples where only 1 ml plasma was available), leaving 33 
banked specimens from 31 patients available for study. Of  the 669 prospectively collected samples, 15 were 
low yield and 3 failed library construction, and another 19 had poor quality sequencing (as suggested by 
median absolute deviation [MAD] score > 0.2, see Methods). Two of  the patient identification (ID) codes 
could not be linked to their medical record, leaving 630 prospectively collected samples from 109 patients 
available for study. In our previous study, there was no statistically significant difference in cfDNA yield 
and TFx between banked and prospectively collected specimens (17), and in this current study, there were 
no obvious differences in these parameters, fragment length, or sequencing quality between the banked and 
prospectively collected specimens. Thus, we combined these sample sets for a total of  663 samples from 
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140 patients for this analysis (median, 3 samples/patient; range, 1–20). The number of  samples per patient, 
the current (or most recent) treatment at the time of  first cfDNA collection, and the number of  treatment 
switches or additions during longitudinal monitoring are summarized in Table 1.
Correlation of  TFx with clinical parameters. To better understand the role of  TFx as a clinical biomarker, 
we sought to determine the relationship of  TFx with PSA and clinical features associated with overall sur-
vival in patients with mCRPC. A recently described multivariable analysis demonstrated that independent 
prognostic features in mCRPC patients treated with docetaxel were Eastern Cooperative Oncology Group 
(ECOG) performance status, alkaline phosphatase, hemoglobin, lactate dehydrogenase (LDH), and num-
ber of  metastases (18). For our analysis, we focused on the time point during longitudinal monitoring when 
TFx was measured highest as a uniform way to account for the heterogeneity in the number of  samples per 
patient. TFx positively correlated with PSA (r = 0.41, P < 0.0001) and alkaline phosphatase (r = 0.47, P < 
0.0001). In contrast, there was a negative correlation between hemoglobin (r = –0.49, P < 0.0001) and TFx 
(Figure 2, A–C). LDH is not routinely checked at our institution, so TFx was unable to be correlated with 
this parameter.
Next, we examined the correlation of  TFx with sites of  metastasis, as determined through convention-
al CT imaging (n = 138), and number of  bone metastases visualized by Technetium-99m skeletal scintigra-
phy (n = 140). The presence or absence of  metastases involving lymph nodes did not correlate with TFx (P 
= 0.74). However, TFx was significantly associated with the presence (Figure 2D) and number (Figure 2E) 
of  bone metastases — median TFx was 0.014 with no bone metastases, 0.047 with 1–3 bone metastases, 
and 0.190 for 4+ bone metastases; P < 0.0001. TFx was also associated with the site of  metastasis — medi-
an TFx was 0.34 with distant visceral metastases, 0.077 with bone metastases (without visceral metastases), 
0.018 with lymph node–only metastases, and 0.009 with no visualized metastases (P < 0.0001) (Figure 2F 
and Table 2).
We included variables that were significantly associated with TFx on univariate analyses into a multi-
variable model to assess for whether the associations remained. In the model, the location of  metastasis, 
hemoglobin, and alkaline phosphatase were still associated with TFx (Table 3). Patients with distant metas-
tasis (lung, liver, and brain) were likely to have a higher TFx compared with patients with bone, nodal, or 
no metastasis. Lower levels of  hemoglobin and higher levels of  alkaline phosphatase were associated with 
higher TFx. PSA was not independently associated with TFx in this multivariable model.
Correlation of  TFx with response to therapy. We next examined changes in TFx over longitudinal 
monitoring in 50 patients meeting criteria for this analysis, as described in the Methods. Changes in 
Figure 1. Schema of the clinical cohort. Diagram depicting reasons for excluding samples from the 722 total collected 
specimens (from 164 patients) to yield 663 samples (from 140 patients) amenable to analysis
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TFx and PSA in 3 patients who responded and then became resistant to cytotoxic chemotherapy, as 
suggested by PSA changes, are depicted in the left panels of  Figure 3. Patient 35 had a rising PSA 
while being treated with estradiol/leukine and then responded — and subsequently became resistant 
— to docetaxel chemotherapy. Patient 82 initially responded and subsequently became resistant to 
enzalutamide in combination with an investigational agent; the patient then responded and subse-
quently became resistant to cabazitaxel and then did not experience a response to the combination of  
docetaxel and carboplatin. Patient 85 responded and subsequently became resistant to cabazitaxel, but 
the patient did not respond to the combination of  docetaxel and carboplatin or mitoxantrone.
In all 3 patients, changes in TFx mirrored changes in PSA, suggesting that these changes likely reflect 
changes in disease burden with response and resistance to therapy. Indeed, all new treatments that led to 
≥30% PSA decline at ≥6 weeks were associated with a decline in TFx from baseline (n = 16, median TFx 
change, –92.2%; range, –70.3% to –100%) when baseline TFx was >7%. TFx of  >7% was chosen as a 
threshold for this analysis, as fluctuating values up to ~0.07 were seen in patients during periods of  dis-
ease stability (Supplemental Figure 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.122109DS1).
We observed that the magnitude of  change in TFx was not always concordant with the degree of  
change in PSA, as some patients had a decline in TFx by an order of  magnitude or more but had only mod-
est decreases in PSA. This suggests that TFx and PSA are not interchangeable biomarkers and represent 
different features of  tumor burden and/or biology.
Longitudinal monitoring of  non–tumor-derived cfDNA. Accurate estimation of  the fraction of  cfDNA 
in the circulation derived from cancerous tissues allows us to estimate the total quantity of  tumor-de-
rived cfDNA per 1 ml of  plasma, which can be expressed as TFx × total cfDNA yield (ng cfDNA/ml 
of  plasma). Likewise, the total yield of  cfDNA derived from noncancerous tissues can be expressed as 
(1 – TFx) × total cfDNA yield (ng cfDNA/ml of  plasma). The total cfDNA yield, the tumor-derived 
cfDNA yield, and the non–tumor-derived cfDNA yield for patients 35, 82, and 85 are shown in the 
right panels of  Figure 3. There appears to be more variability in the measurements of  total cfDNA 
yield and tumor-derived cfDNA yield, as compared with calculated TFx in longitudinal monitoring, 
in consonance with our previous findings in TNBC (17). In addition, changes in TFx appear to track 
Table 1. Description of the patient cohort by number of patients meeting the specified criteria
Number of samples per pt n Treatment at first cfDNA draw n Treatment Switches/AdditionsA n
1 51 LHRH-A alone 10 Nilutamide 4
2 18 Bicalutamide 17 Sipuleucel-T 2
3 16 Estradiol/leukine 1 Abiraterone 21
4 8 Nilutamide 6 Enzalutamide 10
5–10 23 Sipuleucel-T 3      +investigational agent 14
11–20 24 Abiraterone 24 Ketoconazole 1
     +investigational agent 8 Docetaxel 10
Prior chemo for HSPCB 16 Enzalutamide 25      +carboplatin 3
Prior chemo for CRPCB 37      +investigational agent 10 Cabazitaxel 7
Ketoconazole 2 Radium-223 4
Docetaxel 9 Olaparib 4
     +investigational agent 1 Mitoxantrone 1
     +carboplatin 3 Investigational agent 3




Best Supportive Care 5
Investigational Agent 3
AAfter first cfDNA draw, with a plasma sample drawn for cfDNA analysis subsequent to the treatment switch/addition. An individual patient can have 
multiple treatment changes over the course of monitoring. BPrior to first cfDNA draw.
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more closely with PSA changes than changes in total cfDNA yield and tumor-derived cfDNA yield, 
suggesting that TFx is likely a better biomarker of  disease dynamics than these other parameters. (The 
complete data set for TFx, total cfDNA yield, tumor cfDNA yield, and normal cfDNA yield, as well as 
PSA over time for the 50 patients included in this analysis, is included in Supplemental File 1; correla-
tion of  total cfDNA yield with clinical parameters as in Figure 2 is depicted in Supplemental Figure 
3). Interestingly, the total yield of  cfDNA derived from both tumor and noncancerous tissues tracked 
similarly with TFx. This suggests that the quantity of  DNA in the circulation derived from noncancer-
ous tissues is not static and correlates with changes in tumor burden.
One might expect that taxane chemotherapy would lead to ongoing tissue damage to noncancerous 
cells in the body that would be detected as an increase in non–tumor-derived cfDNA while on treatment. 
However, such an increase is not seen in these 3 patients over the time points examined. We cannot rule 
out temporary increases a few hours or days after each infusion that were not captured during longitudinal 
monitoring; however, the dosing schedule of  these agents every 3 weeks suggests that they should continue 
to have some biological activity by the time the next dose is due.
Similarly, one might expect that radiation therapy, both external beam radiation therapy (EBRT) and 
Radium-223, would lead to ongoing damage to noncancerous tissues that would lead to an increase in 
non–tumor-derived cfDNA. Three patients treated with radiation are depicted in Figure 4. Patient 20 was 
treated with EBRT to the cervical and thoracic spine, followed by treatment with Radium-223; at day 406, 
Figure 2. Correlation of TFx with clinical features. (A–C) Scatter plots depicting the relationship between TFx at the time point during longitudinal moni-
toring when the highest TFx value was seen with PSA (A), hemoglobin (B), and alkaline phosphatase (C) at that time point. Each dot represents an individ-
ual patient (n = 140). Spearman correlation coefficients are noted in the corner of each plot. (D–F) Box plots depicting the relationship between TFx at the 
time point during longitudinal monitoring when the highest TFx value was calculated with presence or absence of bony metastases by skeletal scintigra-
phy (n = 140) (D), number of bony metastases detected by skeletal scintigraphy (n = 140) (E), and site(s) of metastasis detected by bone scintigraphy and/
or CT imaging at that time point (n = 138) (F). “Nodal only” denotes macrometastatic disease involving lymph nodes but not distant bony or visceral sites. 
“Bone only” denotes metastatic disease involving bone (+/– lymph nodes) but not distant visceral sites. “Visceral mets” denotes involvement of distant 
visceral sites (liver, lung, brain, adrenal gland) and does not include extension of local disease (i.e., to bladder/ureter or rectum.) Each patient is represent-
ed by a single value within the box plots in each figure (i.e., no patient is represented more than once). Two-sided P values per Wilcoxon rank sum test.
6insight.jci.org   https://doi.org/10.1172/jci.insight.122109
C L I N I C A L  M E D I C I N E
there was a high yield of  cfDNA derived from both cancerous and noncancerous tissues, but the subsequent 
time points showed a return of  cfDNA yield to baseline, despite ongoing treatment with Radium-223. 
Patient 19 had a plasma specimen collected for cfDNA while he was undergoing EBRT to the prostate bed 
— cfDNA from this time point showed a notable increase in TFx and tumor-derived cfDNA yield but only 
a slight increase in non–tumor-derived cfDNA. Patient 83 had cfDNA collected soon after completion of  
EBRT to the spine, and cfDNA from this time point demonstrated no increase in cfDNA from tumor-de-
rived or non–tumor-derived tissue.
TFx in patients maintained on secondary hormonal therapy. As in the clinical trials demonstrating a survival ben-
efit to abiraterone (19) and enzalutamide (20), it is standard practice for patients receiving these agents to remain 
on therapy until clinical or radiographic progression, even when PSA is rising. Three patients who remained on 
enzalutamide or abiraterone for >100 days after initial PSA rise on therapy are depicted in Figure 5. Unlike the 
patients in Figure 3 and Figure 4, where changes in TFx mirrored PSA closely, here we see fluctuations in TFx 
that do not correlate with PSA changes. These changes are not artifactually related to variability in cfDNA yield, 
as the cfDNA yield from tumor and noncancerous tissues depicted in the right panels do not obviously correlate 
with the TFx changes. These cases were manually reviewed to confirm accuracy of results generated by ichorC-
NA, and visual inspection of genome-wide copy number plots showed increases and decreases in the amplitude 
of detected copy number changes concordant with TFx changes as calculated by ichorCNA (Supplemental 
Figure 2). Taken together, we believe that these TFx changes represent bursts of increased tumor-derived cfDNA 
in the circulation during a period of consistently rising PSA but radiographic stability.
Discussion
Here, we present results of longitudinal monitoring of TFx in cfDNA from 663 prospectively collected and 
banked plasma samples from 140 patients with CRPC. We have described the correlation of TFx with clinical 
parameters associated with overall survival in mCRPC, and we have demonstrated that PSA declines with 
treatment initiation were associated with declines in TFx. We also observed that changes in TFx appear to 
track more consistently with PSA than changes in total cfDNA or tumor-derived cfDNA, suggesting that TFx 
is a more reliable biomarker of disease activity than these parameters. TFx during longitudinal monitoring on 
secondary hormonal therapy can fluctuate dramatically, and cfDNA derived from noncancerous tissues is also 
dynamic. These observations may lead to mechanistic insights into processes that induce increases in cfDNA 
derived from both cancerous and noncancerous tissues in the bloodstream and have therapeutic implications.
Table 2. Associations between tumor fraction and location of metastasis in univariate analysis
n Median Q1 Q3 P value
Bone mets <0.0001
     No 25 0.014 0.01 0.03
     Yes 115 0.13 0.04 0.38
Nodal mets 0.74
     No 67 0.08 0.02 0.35
     Yes 71 0.08 0.02 0.29
Liver mets <0.0001
     No 125 0.05 0.02 0.26
     Yes 13 0.37 0.20 0.66
Number of bone mets <0.0001
     0 25 0.014 0.01 0.031
     1–3 33 0.047 0.022 0.164
     4–9 20 0.19 0.034 0.407
     10+ 62 0.19 0.047 0.507
Types of mets <0.0001
No mets 7 0.009 0 0.028
Nodal only 17 0.018 0.012 0.05
Bone (no visceral) 95 0.077 0.025 0.29
Distant visceral 21 0.34 0.16 0.52
Mets, metastasis; Q1, quartile 1; Q3, quartile 3.
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TFx was positively correlated with PSA and alkaline phosphatase in our study, as has been observed in a 
previous report (21); however, negative correlation with hemoglobin was not seen in this previous report. Poten-
tial reasons for this discrepancy include different methods for estimating TFx, as well as different methods to 
assess for correlation; in our study, we correlated hemoglobin with TFx as a continuous variable, whereas in the 
prior study, hemoglobin was correlated with TFx as binned into 3 levels (undetectable, 2%–30%, and >30%). In 
our multivariable analysis, TFx positively correlated with alkaline phosphatase and negatively correlated with 
hemoglobin, but it was not significantly correlated with PSA. These results suggest that the absolute PSA value 
is not independently related to disease burden across patients, which is expected, given that aggressive variant 
prostate cancers with predilection to visceral metastases (22), as well as cancers that dedifferentiate with resis-
tance to therapy (23), often produce relatively low levels of PSA. This finding is also consistent with a recent 
multivariable analysis that demonstrated that alkaline phosphatase, hemoglobin, and number of metastases 
were independent predictors of overall survival in patients with mCRPC, while PSA was not (18). This may 
be because hemoglobin and alkaline phosphatase are parameters that are more consistently and predictably 
affected by organ involvement (primarily bone and liver) across patients with similar disease burden. While 
our heterogeneous patient cohort with a limited number of patients with >2 samples analyzed did not allow a 
rigorous statistical analysis of TFx as an independent prognostic or predictive biomarker, we demonstrated that 
TFx correlated with many of the same features that are prognostic for overall survival in a similar population.
Our findings demonstrate that the TFx in cfDNA is higher in patients with distant visceral metas-
tases (particularly the liver) as compared with those with lymph node or bone metastases. It is unclear 
whether this is due to burden of  disease, acquisition of  more aggressive disease biology late in cancer 
progression, or the anatomy and blood flow of  the metastatic milieu of  the visceral sites. This finding 
is in consonance with a previous autopsy study that demonstrated that, in a patient with metastatic 
neuroendocrine prostate cancer, tumor-derived DNA in the blood had higher contribution from liver 
metastases than metastases from other sites (24). One important translational impact of  these findings is 
prediction of  which patients (or time points from patients) are unlikely to have detectable tumor-derived 
cfDNA. For instance, clinical cfDNA tests are less likely to detect tumor mutations in patients with nor-
mal hemoglobin (Hgb) and alkaline phosphatase, no visceral metastases, or low-volume bone metastases 
or patients who are responding to therapy; however, cfDNA testing is more likely to detect tumor muta-
tions at the time of  progression in these patients.
Monitoring of  cfDNA with initiation of  systemic treatments for mCRPC demonstrated that hormonal 
therapies and chemotherapies that led to a PSA decline of  ≥30% at 6 weeks from treatment initiation also 
led to a decrease in TFx. This is concordant with a prior study demonstrating that TFx was lower in plasma 
from patients at the time of  response to abiraterone compared with the time of  treatment progression (25), 
as well as the observation that a decrease in cfDNA concentration correlated with outcome for the PARP 
inhibitor olaparib in the Phase II Trial of  Olaparib in Patients with Advanced Castration Resistant Prostate 
Cancer (TOPARP-A) (5). This finding would suggest that decrease in TFx with treatment initiation carries 
the potential for assessment of  initial treatment response in cancers without a serum biomarker and cancers 
Table 3. Associations between tumor fraction and location of metastasis, PSA, Hgb, and Alk phos in 
multivariable model
Variable Estimate Error P value
Intercept 0.6620 0.1493
Mets location 0.042
No mets 0 .
Nodal 0.0265 0.08145 
Bone 0.1065 0.07062
Visceral 0.1926 0.08239 
PSA –3.92E-6 0.000013 0.7561
Hgb –0.04876 0.009776 <0.0001
alkaline phosphatase 0.000144 0.000063 0.0227
Mets, metastasis. 
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without measurable disease (e.g., bone-only metastases). This assay may allow for disambiguation of  radio-
graphic flare responses or pseudoprogression, for example, to hormonal therapies and immunotherapeutics. 
Indeed, a favorable circulating tumor DNA profile using a different assay has been reported to accurately dif-
ferentiate pseudoprogession from true progression in melanoma (26). TFx could also serve as an early bio-
marker of  disease response to allow for earlier switch or intensification of  therapy. The use of  TFx decline as 
an early biomarker of  response to therapy should be validated prospectively.
In addition, dense longitudinal monitoring across this heterogeneous cohort has demonstrated unex-
pected findings that warrant further study. First, the total yield of  cfDNA derived from both tumor and 
noncancerous tissues appears to track with TFx. The fact that cfDNA derived from noncancer cells tends 
to decrease and increase in response to progression of  therapy suggests that the same process that leads to 
tumor-derived DNA in the circulation also contributes to cfDNA from these noncancerous elements. These 
could include tumor-associated cells (e.g., fibroblasts, endothelial cells, inflammatory infiltrate), normal 
cells from the metastatic niche (e.g., hepatocytes, osteoblasts/osteoclasts), or cell populations not originat-
ing in the tumor (e.g., leukocytes, other BM-derived cell populations). Detection of  tissue-specific methyl-
ation patterns in cfDNA (27–29) may allow us to identify tissue of  origin of  these noncancerous elements.
Interestingly, DNA from noncancerous cells in the circulation does not increase in response to initia-
tion of  chemotherapy, external beam radiation, or Radium-223 at a subsequent time point 3–4 weeks from 
treatment start (though there may be a short-term increase that is not captured at the time scale of  our lon-
gitudinal sampling). This suggests that cfDNA in the circulation is not simply associated with tissue injury, 
as there is certainly ongoing tissue injury from chemotherapy and radiation that would not be expected to 
be associated with treatment with abiraterone/enzalutamide, for example. Of note, a single blood draw was 
obtained in this cohort on a day when a patient was actively receiving radiation therapy, and at that time 
point, we did see an increase in TFx but not a pronounced increase in cfDNA derived from noncancerous 
tissues compared with surrounding time points.
Figure 3. Tumor fraction and cfDNA yield with PSA over time in 3 patients receiving chemotherapy. Left panels: Depiction of TFx (orange markers, left 
axis) and PSA (blue markers, right axis) over time (measured in days) for 3 patients in the cohort treated with chemotherapy. Start and stop dates for 
treatments are depicted with a diamond; lines continuing to the edge of the graph without a diamond denote that the therapy was initiated prior to the 
time points depicted in the graph or completed after the time points depicted in the graph. IA, investigational agent. Two markers from the same time 
point on day 120 for patient 85 denote replicates from the same cfDNA isolate but with independent library construction and sequencing steps. Right 
panels: Depiction of total cfDNA yield (in ng/ml of plasma, lavender), tumor DNA yield (TFx × total cfDNA yield, orange), and noncancerous (“normal”) DNA 
yield ([1 – TFx] × total cfDNA yield, blue) in the same 3 patients over time. Note that the scales of total cfDNA yield (y axes) are different for the 3 patients.
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Our data demonstrate discordance in magnitude of  changes in TFx vs. PSA with response to ther-
apy, as well as unexpected fluctuations in TFx during periods of  overall disease stability for patients 
receiving secondary hormonal therapy. Both findings suggest that our understanding of  processes lead-
ing to changes in TFx is incomplete. Indeed, other studies suggest that cfDNA in the circulation may 
be more related to tumor metabolism than tumor burden (30). We hypothesize that there are short-term 
processes, such as inflammatory or metabolic stresses, leading to bursts of  cfDNA release that do not 
necessarily reflect increased tumor burden. As such, a rise in TFx while undergoing treatment is not a 
reliable indicator of  disease progression and should not be used to withdraw a patient from therapy. We 
are actively investigating the properties of  the tumor-derived and noncancerous elements present during 
these bursts of  cfDNA release to suggest the biological underpinnings. Given the short half-life of  
cfDNA (estimates range from 16 minutes to several hours; ref. 31) in relation to longer-term changes in 
tumor dynamics that would be captured through a protein-based circulating biomarker or radiographic 
changes, we posit that examination of  circulating cfDNA provides a window into short-term processes 
that would not easily be assayed through other means.
Although our study focused on using ULP-WGS of cfDNA to quantify TFx and explore its association 
with clinical parameters in mCRPC, ULP-WGS has also enabled noninvasive tracking of  somatic copy num-
ber alterations and structural variants (2, 3, 11). For instance, serial analysis of  cfDNA has revealed changes 
in focal amplifications in the tumors of  mCRPC patients over the course of  therapy (10). Previously, deep 
targeted sequencing of  cfDNA from pretreatment plasma specimens from patients treated with abiraterone 
or enzalutamide revealed genetic alterations in AR, TP53, ATM, and BRCA2 that were associated with rapid 
resistance to therapy (21). ULP-WGS has the capability of  detecting certain copy number alterations (par-
ticularly losses) or signatures (e.g., tandem duplicator phenotype; ref. 32) that would not be easily detectable 
through targeted sequencing, and we hypothesize that a subset of  these, such as copy losses of  PTEN, RB1, 
or DNA damage repair genes, would have prognostic and predictive utility. Accordingly, further analyses of  
ULP-WGS data are underway from specimens obtained in the context of  completed and currently accruing 
Figure 4. Tumor fraction and cfDNA yield with PSA over time in 3 patients receiving radiation therapy. Left panels: Depiction of TFx and PSA over 
time for 3 patients in the cohort treated with radiation therapy (RT). Note that only patient 19 had plasma collected for cfDNA on a day when he received 
external beam radiation therapy. Two markers from the same time point on days 112 and 196 for patient 20, and on day 196 for patient 19 denote replicates 
from the same blood draw but with independent cfDNA isolation, library construction, and sequencing steps. Right panels: Depiction of total cfDNA yield, 
tumor DNA yield, and noncancerous (“normal”) DNA yield over time in the same 3 patients.
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clinical trials to derive TFx and characterize copy number alterations and to correlate these features with 
clinical outcomes in these trials. We anticipate that ULP-WGS will be a complementary approach to targeted 
sequencing: clinical applications for the combination of  ULP-WGS with deep targeted sequencing include 
(a) revealing a set of  genetic features to inform prognosis and optimize initial treatment selection; (b) assess-
ing for initial therapeutic response such that a suboptimal reduction in TFx on-treatment as determined by 
ULP-WGS would allow for earlier treatment intensification or discontinuation; and (c) revealing new genetic 
features after therapeutic resistance that would allow for optimal selection of  subsequent treatments.
In conclusion, our study demonstrates the potential role of  TFx as a clinically relevant biomarker that 
warrants further study as a prognostic feature and as an early marker of  response to therapy. If  validated, it 
would be particularly useful in cancer types without a reliable serologic biomarker. As a relatively low-cost, 
noninvasive test that is easily accessible by standard phlebotomy, deriving tumor fraction from ultra–low pass 
whole genome sequencing has the potential to be broadly disseminated to help guide clinical decision making.
Methods
Human subjects. Eligible CRPC patients were identified through the Prostate Clinical Research Information 
System (CRIS) database at Dana-Farber Cancer Institute (33). The CRIS system comprises data-entry soft-
ware, a central data repository, collection of  patient data including comprehensive follow-up of  all patients, 
and tightly integrated security measures, as previously described (33). The cohorts accrued to this study 
were patients who either (a) were identified based on prospective chart review to have PSA >20 ng/ml, 
progressive disease based on rising PSA, and scan progression; (b) were participants in a Phase I study of  
crizotinib in combination with enzalutamide (DF/HCC protocol no. 14-230, NCT02207504) or a Phase 
Ib study of  abiraterone in combination with ARN-509 (DF/HCC protocol no. 12-338, NCT01792687); (c) 
were eligible for metastasis biopsy after progression on enzalutamide or abiraterone through the Stand Up 
2 Cancer/PCF Dream Team effort based on participation in a Phase II study of  abiraterone in combination 
with dutasteride (DF/HCC protocol no. 10-448, NCT01393730), a Phase II trial of  enzalutamide with 
Figure 5. Tumor fraction and cfDNA yield with PSA over time in 3 patients receiving AR-targeted therapy. Left panels: Depiction of TFx and PSA over 
time for 3 patients in the cohort treated with abiraterone or enzalutamide for >100 days with rising PSA. Two markers from the same time point on days 
28 and 112 for patient 24, and on day 85 for patient 31, denote replicates from the same blood draw but with independent cfDNA isolation, library con-
struction, and sequencing steps. Two markers from the same time point on day 71 for patient 31 denote replicates from the same cfDNA isolate but with 
independent library construction and sequencing steps. Right panels: Depiction of total cfDNA yield, tumor DNA yield, and noncancerous (“normal”) DNA 
yield over time in the same 3 patients.
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correlative assessment of  AR signaling (DF/HCC protocol no. 13-301, NCT01942837), a Phase II trial 
of  abiraterone without exogenous glucocorticoids (DF/HCC protocol no. 13-449, NCT02025010), or a 
tumor biopsy protocol to assess tissue correlates of  therapeutic response (DF/HCC protocol no. 09-171); 
or (d) had frozen plasma banked prior to treatment with carboplatin or a taxane through a tissue and blood 
specimen banking protocol (DF/HCC protocol no. 01-045). Patients in all of  these cohorts had castra-
tion-resistant disease, but participants in trial 13-449 were not required to have radiographically detectable 
metastases. Sampling of  plasma from multiple time points could be done during clinical trial or standard 
of  care treatment if  the patient had consented to protocol banking protocol DF/HCC protocol no. 01-045. 
Medical record review was approved by the IRB per DF/HCC protocol no. 18-135.
Clinical specimens. Prospectively collected venous blood samples (10 cc) were collected in EDTA (BD 
Biosciences) or CellSave Preservative (Cell Search) tubes. Blood was processed to component plasma, buffy 
coat, and erythrocytes within 4 hours of  collection through standard density gradient centrifugation. Plas-
ma samples were subjected to an additional high-speed spin at 19,000 g for 10 minutes, and plasma was fro-
zen at –80°C until further processing. Plasma specimens banked under protocol no. 01-045 were processed 
from blood using standard methods at the time of  collection (i.e., without an additional high-speed spin 
that is performed for prospectively collected samples and with an uncertain gap between blood collection 
and plasma processing up to ~8 hours) and were subsequently frozen. Frozen aliquots of  plasma were 
thawed at room temperature, and banked plasma specimens were subjected to high-speed spin after thaw-
ing. CfDNA was extracted from plasma (4 ml plasma from prospectively collected specimens; 1 ml from 
banked specimens) using the Qiagen Circulating DNA kit on the QIAsymphony liquid handling system. 
Quantification of  extracted cfDNA was performed using the PicoGreen (Invitrogen) assay on a Hamilton 
STAR-line liquid handling system.
ULP-WGS. Library construction of  cfDNA was performed using the Kapa HyperPrep kit with custom 
adapters (Integrated DNA Technologies). Generally, 3–20 ng of  cfDNA input (median 5 ng, 1,000–7,000 
haploid genome equivalents) was used for ULP-WGS. A Hamilton STAR-line liquid handling system was 
used to automate and perform this method. Constructed sequencing libraries were pooled (2 μl of  each × 96 
per pool) and sequenced using 100 bp paired-end reads over 1 lane on a HiSeq2500 (Illumina) for ULP-WGS.
Analysis of  ULP-WGS data. ULP-WGS of  cfDNA was performed to average genome-wide fold coverage 
of  0.1×. Segment copy number and TFx were derived via ichorCNA (2). Briefly, the genome is divided into 
nonoverlapping windows, or bins, of  1 Mb, and aligned reads are counted based on overlap within each 
bin using the tools in HMMcopy Suite1 (http://compbio.bccrc.ca/softwar/hmmcopy/). Centromeres are 
filtered based on chromosome gap coordinates obtained from UCSC for hg19, including one 1 Mb bin up- 
and downstream of  the gap. The read counts are then normalized to correct for GC-content and mappability 
biases using HMMcopy R package. Log2 copy ratios were computed for each bin relative to ULP-WGS data 
from a reference panel of  27 healthy donors. The cancer patient cfDNA CNA signals is composed of  an 
admixture between DNA fragments derived from tumor and nontumor cells so discrete copy number predic-
tion and TFx estimation is derived using a hidden Markov model. The copy number states can be mapped to 
integer values corresponding to hemizygous deletions (HETD, 1 copy), copy neutral (NEUT, 2 copies), copy 
gain (GAIN, 3 copies), amplification (AMP, 4 copies), and high-level amplification (HLAMP, 5 copies). Of  
note, homozygous deletion states typically occur at smaller scales than the bin sizes used for the analysis 
and are therefore excluded. Further assumptions of  the model are described in ref. 2. Samples were exclud-
ed if  the MAD of  the copy ratios (log2 ratio) between adjacent bins, genome-wide, was greater than 0.20, 
suggesting poor-quality sequence data. Genome-wide copy number plots were generated by ichorCNA. The 
software ichorCNA is available at https://github.com/broadinstitute/ichorCNA.
Data availability. Sequencing data available upon request under dbGaP accession code phs001417.
Statistics. All statistical analyses and data visualizations were performed in SAS 9.4 and R version 3.3.1. 
Spearman’s correlation was used to summarize correlation of  PSA, alkaline phosphatase, and hemoglobin 
levels with TFx. Wilcoxon’s rank sum test was used to assess the association between TFx and metasta-
sis site. For the multivariable analysis, a linear mixed effects model with restricted maximum likelihood 
(REML) method for variance was used to assess the association between location of  metastasis, PSA, hemo-
globin, alkaline phosphatase, and TFx. We performed 2-sided testing for all statistical tests, and we consid-
ered a nominal P value less than 0.05 to be significant. Analyses from longitudinal monitoring of  TFx were 
restricted to patients with more than 1 plasma sample that passed the quality checks in Figure 1 with TFx 
measured at >0.07 at any time point during longitudinal monitoring. TFx of  0.07 was chosen as a threshold, 
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as fluctuating values up to 0.07 were seen in patients during periods of disease stability (Supplemental Figure 1). 
We also wanted to focus our analyses above this threshold to mitigate the effect of  measurement error at or 
near the lower limit of  detection of  0.03, given a MAD of  error of  ≤0.014 for TFx estimation (2).
Study approval. The present studies in humans were reviewed and approved by the IRB of  the DF/
HCC. Subjects provided written informed consent to allow the collection of  tissue and blood and analysis 
of  clinical and genetic data for research purposes, as well as data sharing through DF/HCC protocol no. 
11-104 (Profile - Research on Clinically Acquired Patient Material in Cancer), no. 01-045, or no. 09-171. 
Medical record review was approved by the IRB per DF/HCC protocol no. 18-135.
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